CAPR Stock Overview
A clinical-stage biotechnology company, focuses on the development of transformative cell and exosome-based therapeutics for the treatment of duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Capricor Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$4.57 |
| 52 Week High | US$7.28 |
| 52 Week Low | US$2.68 |
| Beta | 4.02 |
| 11 Month Change | 12.56% |
| 3 Month Change | -19.54% |
| 1 Year Change | -30.86% |
| 33 Year Change | -8.96% |
| 5 Year Change | 71.16% |
| Change since IPO | -89.12% |
Recent News & Updates
Recent updates
Investors Don't See Light At End Of Capricor Therapeutics, Inc.'s (NASDAQ:CAPR) Tunnel
Jul 30
Here's Why Capricor Therapeutics, Inc.'s (NASDAQ:CAPR) CEO May Have Their Pay Bumped Up
May 08Benign Growth For Capricor Therapeutics, Inc. (NASDAQ:CAPR) Underpins Stock's 26% Plummet
Apr 19We're Not Very Worried About Capricor Therapeutics' (NASDAQ:CAPR) Cash Burn Rate
Apr 16Capricor Therapeutics, Inc.'s (NASDAQ:CAPR) 25% Dip In Price Shows Sentiment Is Matching Revenues
Feb 03Is Capricor Therapeutics (NASDAQ:CAPR) In A Good Position To Invest In Growth?
Dec 13Here's Why We're Not Too Worried About Capricor Therapeutics' (NASDAQ:CAPR) Cash Burn Situation
Aug 13A Look At The Fair Value Of Capricor Therapeutics, Inc. (NASDAQ:CAPR)
Nov 03Capricor Therapeutics GAAP EPS of -$0.29 misses by $0.03
Aug 10Companies Like Capricor Therapeutics (NASDAQ:CAPR) Are In A Position To Invest In Growth
Feb 01We Think Capricor Therapeutics (NASDAQ:CAPR) Can Afford To Drive Business Growth
Oct 14Capricor Therapeutics Announces Another 'Final' 12-Month P2 Duchenne Muscular Dystrophy Trial Result
Sep 25Capricor Therapeutics slumps 9% on $75M stock offering
Jun 21Capricor Therapeutics (NASDAQ:CAPR) Is In A Good Position To Deliver On Growth Plans
May 16When Will Capricor Therapeutics, Inc. (NASDAQ:CAPR) Turn A Profit?
Mar 13Shareholder Returns
| CAPR | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 0.2% | 0.1% | 0.06% |
| 1Y | -30.9% | 13.8% | 22.6% |
Return vs Industry: CAPR underperformed the US Biotechs industry which returned 15.2% over the past year.
Return vs Market: CAPR underperformed the US Market which returned 22.2% over the past year.
Price Volatility
| CAPR volatility | |
|---|---|
| CAPR Average Weekly Movement | 8.2% |
| Biotechs Industry Average Movement | 10.4% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 15.0% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: CAPR's share price has been volatile over the past 3 months.
Volatility Over Time: CAPR's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2005 | 102 | Linda Marbán | www.capricor.com |
Capricor Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development of transformative cell and exosome-based therapeutics for the treatment of duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs. The company’s lead candidate, CAP-1002, an allogeneic cardiac-derived cell therapy, which has completed phase 3 clinical trial for the treatment of patients with late-stage Duchenne muscular dystrophy (DMD). It also focused on developing StealthX, an engineered exosome-based vaccine candidate, under phase 1 clinical study for a range of therapeutic applications, including targeted RNA, protein, and small molecule therapeutics to treat or prevent a variety of diseases.
Capricor Therapeutics, Inc. Fundamentals Summary
| CAPR fundamental statistics | |
|---|---|
| Market cap | US$152.93m |
| Earnings (TTM) | -US$27.95m |
| Revenue (TTM) | US$27.15m |
5.5x
P/S Ratio-5.3x
P/E RatioIs CAPR overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CAPR income statement (TTM) | |
|---|---|
| Revenue | US$27.15m |
| Cost of Revenue | US$37.40m |
| Gross Profit | -US$10.25m |
| Other Expenses | US$17.70m |
| Earnings | -US$27.95m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.86 |
| Gross Margin | -37.73% |
| Net Profit Margin | -102.93% |
| Debt/Equity Ratio | 0% |
How did CAPR perform over the long term?
See historical performance and comparison